In conclusion, we developed comprehensive network pharmacology to identify targets of celastrol in AIH and preliminary confirmed the suppressed PI3K/AKT pathway-mediated treatment efficacy in two typical rodent models. The gene discussed is AKT1; the disease is autoimmune hepatitis.